Citius Pharmaceuticals, Inc. Logo

Citius Pharmaceuticals, Inc.

A late-stage biopharmaceutical company developing and commercializing critical care products.

CTXR | US

Overview

Corporate Details

ISIN(s):
US17322U2078
LEI:
Country:
United States of America
Address:
11 COMMERCE DRIVE, 7016 CRANFORD

Description

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company that develops and commercializes critical care products. The company's diversified pipeline focuses on anti-infectives in adjunct cancer care, stem cell therapies, and prescription products. Its portfolio includes LYMPHIR™, an FDA-approved therapy for adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Key product candidates in development include Mino-Lok®, an antibiotic lock solution intended to treat patients with catheter-related bloodstream infections, and Halo-Lido, a topical formulation for the treatment of hemorrhoids. Additionally, the company is advancing a stem cell therapy platform for conditions such as acute respiratory distress syndrome (ARDS).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2019-04-26 18:48
PROSPECTUS SUPPLEMENT
English ZIP 179.8 KB
2019-04-24 18:29 English ZIP 7.7 KB
2019-04-23 18:53 English ZIP 61.0 KB
2019-04-17 18:34
REGISTRATION STATEMENT
English ZIP 213.1 KB
2019-04-08 16:00 English ZIP 8.1 KB
2019-04-05 18:06 English ZIP 9.0 KB
2019-04-05 18:06 English ZIP 8.4 KB
2019-04-03 18:32 English ZIP 212.5 KB
2019-04-01 18:28
PROSPECTUS SUPPLEMENT
English ZIP 141.3 KB
2019-03-20 11:59 English ZIP 130.6 KB
2019-02-19 17:06
CURRENT REPORT
English ZIP 20.3 MB
2019-02-14 17:28
CURRENT REPORT
English ZIP 10.8 KB
2019-02-14 17:18
QUARTERLY REPORT
English ZIP 646.1 KB
2019-02-14 16:05 English ZIP 18.0 KB
2019-01-30 16:55 English ZIP 20.0 KB

Automate Your Workflow. Get a real-time feed of all Citius Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Citius Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Citius Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ABEONA THERAPEUTICS INC. Logo
A clinical-stage biopharma developing cell and gene therapies for rare diseases.
United States of America
ABEO
ABINGDON HEALTH PLC Logo
A CDMO specializing in lateral flow assays, offering development to manufacturing services.
United Kingdom
ABDX
ABIONYX Pharma Logo
Develops biotherapies and drug delivery vectors using apolipoprotein A-I.
France
ABNX
ABIVAX Logo
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
France
ABVX
Abivax S.A. Logo
Clinical-stage biotech developing miRNA therapeutics for inflammatory diseases.
United States of America
ABVX
ABL Diagnostics Logo
Develops molecular diagnostic solutions for managing infectious diseases.
France
ABLD
Abliva Logo
Biopharmaceutical company developing medicines for primary mitochondrial diseases.
Sweden
ABLI
AB Science Logo
Researches and develops protein kinase inhibitors for human and veterinary medicine.
France
AB
ABVC BIOPHARMA, INC. Logo
Develops botanical drugs and medical devices for oncology, ophthalmology, and CNS.
United States of America
ABVC
ACADIA PHARMACEUTICALS INC Logo
Biopharmaceutical company developing medicines for CNS disorders and rare diseases.
United States of America
ACAD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.